6ugc
From Proteopedia
(Difference between revisions)
(New page: '''Unreleased structure''' The entry 6ugc is ON HOLD Authors: Mulligan, V.K., Kang, C.S., Antselovich, I., Sawaya, M.R., Yeates, T.O., Baker, D. Description: C3 symmetric peptide desig...) |
|||
(2 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==C3 symmetric peptide design number 3== | |
+ | <StructureSection load='6ugc' size='340' side='right'caption='[[6ugc]], [[Resolution|resolution]] 0.90Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6UGC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6UGC FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 0.9Å</td></tr> | ||
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CD:CADMIUM+ION'>CD</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ugc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ugc OCA], [https://pdbe.org/6ugc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ugc RCSB], [https://www.ebi.ac.uk/pdbsum/6ugc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ugc ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Cyclic symmetry is frequent in protein and peptide homo-oligomers, but extremely rare within a single chain, as it is not compatible with free N- and C-termini. Here we describe the computational design of mixed-chirality peptide macrocycles with rigid structures that feature internal cyclic symmetries or improper rotational symmetries inaccessible to natural proteins. Crystal structures of three C2- and C3-symmetric macrocycles, and of six diverse S2-symmetric macrocycles, match the computationally-designed models with backbone heavy-atom RMSD values of 1 A or better. Crystal structures of an S4-symmetric macrocycle (consisting of a sequence and structure segment mirrored at each of three successive repeats) designed to bind zinc reveal a large-scale zinc-driven conformational change from an S4-symmetric apo-state to a nearly inverted S4-symmetric holo-state almost identical to the design model. These symmetric structures provide promising starting points for applications ranging from design of cyclic peptide based metal organic frameworks to creation of high affinity binders of symmetric protein homo-oligomers. More generally, this work demonstrates the power of computational design for exploring symmetries and structures not found in nature, and for creating synthetic switchable systems. | ||
- | + | Computational design of mixed chirality peptide macrocycles with internal symmetry.,Mulligan VK, Kang CS, Sawaya MR, Rettie S, Li X, Antselovich I, Craven TW, Watkins AM, Labonte JW, DiMaio F, Yeates TO, Baker D Protein Sci. 2020 Dec;29(12):2433-2445. doi: 10.1002/pro.3974. PMID:33058266<ref>PMID:33058266</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | [[Category: | + | </div> |
- | [[Category: | + | <div class="pdbe-citations 6ugc" style="background-color:#fffaf0;"></div> |
- | [[Category: | + | == References == |
- | [[Category: | + | <references/> |
- | [[Category: | + | __TOC__ |
- | [[Category: | + | </StructureSection> |
- | [[Category: | + | [[Category: Large Structures]] |
+ | [[Category: Antselovich I]] | ||
+ | [[Category: Baker D]] | ||
+ | [[Category: Kang CS]] | ||
+ | [[Category: Mulligan VK]] | ||
+ | [[Category: Sawaya MR]] | ||
+ | [[Category: Yeates TO]] |
Current revision
C3 symmetric peptide design number 3
|